Penn Mutual Asset Management’s Vaxcyte PCVX Stock Holding History

Penn Mutual Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,585	Closed	-$374K	–	68
2022 Q3	$374K	Buy	+15,585	New	+$395K	0.49%	46
2021 Q2	–	Sell	-22,227	Closed	-$439K	–	93
2021 Q1	$439K	Buy	22,227 +12,987	+141%	+$327K	0.5%	30
2020 Q4	$246K	Buy	+9,240	New	+$344K	0.22%	37

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Penn Mutual Asset Management's PCVX Position: Q4 2022 in Review

Penn Mutual Asset Management sold out of Vaxcyte (PCVX) in Q4 2022, closing a stake of 15,585 shares — an estimated $374K sold.

Penn Mutual Asset Management first reported a position in PCVX in Q4 2020 and held it in 3 quarters. The position peaked at $439K in Q1 2021. 198 funds tracked by Wall St. Rank hold PCVX as of Q4 2022.

Penn Mutual Asset Management reported no remaining Vaxcyte position as of Q4 2022 after selling out during the quarter.
Penn Mutual Asset Management sold 15,585 Vaxcyte shares in Q4 2022, an estimated $374K.
Penn Mutual Asset Management first reported a position in Vaxcyte in Q4 2020 and held it in 3 quarters.
Penn Mutual Asset Management's Vaxcyte position peaked at $439K in Q1 2021.
198 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2022.

Based on Penn Mutual Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.